Evanston-based biopharmaceutical company Aptinyx Inc. Thursday said a drug it is studying to treat patients with painful diabetic peripheral neuropathy failed a recent clinical study.The drug, NYX-2925, did not achieve statistically significant separation from a placebo on the study’s primary endpoint, which assessed the change from baseline in average daily pain on the numeric rating scale, the company said.
Related posts
-
Game time: Dave & Buster’s to open at Yorktown Center
Dave & Buster’s is scheduled to open next month at Yorktown Center in Lombard with the... -
Hanover Park parks president speaking out on citation for verbal assault of teen referee
Hanover Park Park District President Mark Elkins is speaking out regarding a Carol Stream citation he... -
Five high school football games to watch this weekend
St. Charles North (3-0) at Batavia (3-0)